<DOC>
	<DOCNO>NCT01711528</DOCNO>
	<brief_summary>This phase I trial study side effect best dose dinaciclib bortezomib give together dexamethasone treat patient multiple myeloma return period improvement . Dinaciclib bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , dexamethasone , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving dinaciclib bortezomib together dexamethasone may kill cancer cell .</brief_summary>
	<brief_title>Dinaciclib , Bortezomib , Dexamethasone Treating Patients With Relapsed Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximally tolerated dos dinaciclib bortezomib , use combination , two different schedule , treatment relapse multiple myeloma . SECONDARY OBJECTIVES : I . To determine toxicity associate dinaciclib bortezomib , use combination , treatment relapse multiple myeloma . II . To determine overall response rate associate dinaciclib bortezomib , use combination , treatment relapse multiple myeloma . III . To explore difference toxicity associate two different schedule dinaciclib bortezomib use combination . TERTIARY OBJECTIVES : I . To examine expression level target cyclin dependent kinase ( CDK ) : CDK 2,5,7 9 level cluster differentiation ( CD ) 138-purified tumor cell , correlate response ( clinical molecular ) determine high low level target CDK expression , present , influence dinaciclib efficacy . II . To examine immunoglobulin ( Ig ) H translocation status , P53 status presence v-myc myelocytomatosis viral oncogene homolog ( avian ) ( Myc ) amplification rearrangement , determine patient bone marrow treatment , use pre validate fluorescence situ hybridization ( FISH ) panel identify common myeloma translocation , correlate molecular and/or clinical marker drug activity , ass specific genetic subgroup myeloma tumor responsive resistant . III . To determine gene expression profile myeloma cell treatment understand role tumor gene dysregulation and/or dinaciclib induced effect transcription . OUTLINE : This dose-escalation study dinaciclib bortezomib . Patients assign 1 2 treatment schedule . SCHEDULE I : Patients receive dinaciclib intravenously ( IV ) 2 hour bortezomib subcutaneously ( SC ) IV ( patient tolerate SC injection ) day 1 , 8 , 15 dexamethasone orally ( PO ) daily ( QD ) day 1 , 2 , 8 , 9 , 15 , 16 . Courses repeat every 28 day absence disease progression unacceptable toxicity . SCHEDULE II : Patients receive dinaciclib IV 2 hour day 1 ; bortezomib SC day 1 8 ; dexamethasone PO QD day 1 , 2 , 8 , 9 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day 3 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Serum creatinine = &lt; 2.5 mg/dL Absolute neutrophil count &gt; = 1000/uL Untransfused platelet count &gt; = 75000/uL Hemoglobin &gt; = 8 g/dL Total bilirubin = &lt; 1.5 time institutional upper limit normal ( ULN ) Patients relapse multiple myeloma already receive one standard treatment regimens Measurable disease multiple myeloma define least ONE following : Serum monoclonal protein &gt; = 1 g/dL &gt; = 200 mg monoclonal protein urine 24 hour electrophoresis Serum immunoglobulin free light chain &gt; = 10 mg/dL abnormal serum immunoglobulin kappa lambda free light chain ratio Monoclonal bone marrow plasmacytosis &gt; = 30 % ( evaluable disease ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 Adequate residual organ function per treat physician discretion ; Note : limit regard number prior therapy Provide inform write consent Negative pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Willing provide sample correlative research purpose Willing return consent institution followup study Recovered ( i.e. , = &lt; grade 1 toxicity ) reversible effect prior antineoplastic therapy Any follow recent therapy : Alkylators ( e.g . melphalan , cyclophosphamide ) = &lt; 14 day prior registration Anthracyclines = &lt; 14 day prior registration High dose corticosteroid , immune modulatory drug ( thalidomide lenalidomide ) , proteosome inhibitor ( bortezomib ) = &lt; 7 day prior registration Concomitant high dose corticosteroid ( concurrent use corticosteroid ) ; EXCEPTION : patient may chronic steroid ( maximum dose 20 mg/day prednisone equivalent ) give disorder amyloid , i.e. , adrenal insufficiency , rheumatoid arthritis , etc . Other active malignancy = &lt; 2 year prior registration ; EXCEPTIONS : nonmelanotic skin cancer carcinoma insitu cervix ; NOTE : history prior malignancy , must receive specific treatment cancer Any following : Pregnant woman woman reproductive ability unwilling use 2 effective method contraception time sign informed consent form 30 day last dose study drug Nursing woman Men unwilling use condom ( even undergone prior vasectomy ) intercourse woman , take drug 30 day stop treatment Other comorbidity would interfere patient 's ability participate trial , e.g . uncontrolled infection , uncompensated heart lung disease Other concurrent chemotherapy , radiotherapy , ancillary therapy consider investigational ; NOTE : bisphosphonates consider supportive care rather therapy , thus allow protocol treatment Peripheral neuropathy &gt; = grade 2 clinical examination screen period Major surgery = &lt; 14 day prior registration Currently take strong moderate inhibitors/inducers cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) ; Note : dinaciclib CYP3A4 substrate ; patient take grapefruit/grapefruit juice St. John 's wort ; use strong moderate CYP3A4 inhibitor prohibit &lt; 7 day prior registration ; use CYP3A4 inducer prohibit = &lt; 7 day prior registration Any following condition : Myocardial infarction = &lt; 6 month prior registration New York Heart Association ( NYHA ) class III IV heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmia Electrocardiographic evidence acute ischemia Active conduction system abnormality ; NOTE : prior study entry , electrocardiogram ( ECG ) abnormality screen must document investigator medically relevant Known hypersensitivity bortezomib , boron , mannitol Serious medical psychiatric illness likely interfere participation clinical study per judgment treating physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>